July 18, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

Basel, 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)... Read more

July 17, 2018 Bio/Pharma/CRO PR/Corporate

Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu

Basel, 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in... Read more

July 17, 2018 Bio/Pharma/CRO PR/Corporate

Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu

Basel, 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in... Read more

July 10, 2018 Bio/Pharma/CRO M&A, Partnerships Mass Spectrometry

908 Devices and Hangzhou Just Biotherapeutics Announce Joint Innovation Partnership

07.10.18 908 Devices, a pioneer of purpose-built analytical devices for chemical and biomolecular analysis, today announced a joint innovation partnership with Hangzhou Just Biotherapeutics (HJB). HJB is an integrated design company focused on technologies that will accelerate development of biotherapeutics and reduce manufacturing costs to make medicines more readily available in the global marketplace. HJB partners... Read more

July 2, 2018 Atomic Spectroscopy Bio/Pharma/CRO Cell Analysis Tools Chromatography Lab Equipment Lab Top-10 Life Science Tools Molecular Spectroscopy

MilliporeSigma to Expand Operations in Gillingham, UK

Jul 02, 2018 Company to expand distribution centre for Life Science products to support future business growth MilliporeSigma, a leading science and technology company, today announced plans to expand its Gillingham, UK distribution centre. The €9 million investment will boost distribution capabilities for the business. Anticipated to open in early 2019, the new facility will... Read more

July 2, 2018 Bio/Pharma/CRO Licensing, IP, and Legal PR/Corporate

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Basel, 02 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple... Read more

June 29, 2018 Bio/Pharma/CRO

Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome

Basel, 29 June 2018 Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome Cytokine release syndrome (CRS), a severe and life-threatening condition, is caused by an overactive immune response and is often associated with the use of chimeric antigen receptor (CAR) T-cell therapy for certain blood cancers RoActemra would be the first... Read more

June 28, 2018 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme

Highlights: Highly synergistic with Agilent’s current customer-base and sales channel Enables complete LC and LC/MS workflow solutions in important glycan biopharma segment Strengthens Agilent’s customer value proposition in fast-growing biopharma market SANTA CLARA, Calif.–(BUSINESS WIRE)–Jun. 28, 2018– Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme,... Read more

June 28, 2018 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme

Highlights: Highly synergistic with Agilent’s current customer-base and sales channel Enables complete LC and LC/MS workflow solutions in important glycan biopharma segment Strengthens Agilent’s customer value proposition in fast-growing biopharma market SANTA CLARA, Calif.–(BUSINESS WIRE)–Jun. 28, 2018– Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme,... Read more

June 28, 2018 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme

Highlights: Highly synergistic with Agilent’s current customer-base and sales channel Enables complete LC and LC/MS workflow solutions in important glycan biopharma segment Strengthens Agilent’s customer value proposition in fast-growing biopharma market SANTA CLARA, Calif.–(BUSINESS WIRE)–Jun. 28, 2018– Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme,... Read more